PROTECT for Rare Act

Bill Number

S. 3551

Origin Chamber

Senate

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-12-17: Read twice and referred to the Committee on Finance.

Last Updated

2026-01-20T15:11:19Z

AI-Generated Summary

Purpose

The "Providing Realistic Opportunity To Equal and Comparable Treatment for Rare Act" (PROTECT for Rare Act) aims to expand health insurance coverage for drugs and biological products used to treat or manage rare diseases or conditions—defined as those affecting 200,000 or fewer individuals in the United States. It seeks to ensure that off-label uses (uses not explicitly approved by the FDA but supported by medical evidence) of such drugs are covered under Medicare, Medicaid, and private health insurance, addressing gaps in access to treatments for rare conditions.

Key Provisions

• Medicare Coverage (Titles XVIII of the Social Security Act):
• Expands the definition of covered drugs under Medicare Part B (outpatient services) to include drugs used for rare diseases or conditions, if supported by peer-reviewed medical literature (including clinical guidelines) and not listed as contraindicated (harmful or not recommended) in FDA-approved labeling or certain drug compendia (standard reference books for drug uses).
• For Medicare Part D (prescription drug benefit), broadens "medically accepted indications" to cover similar off-label uses for rare conditions.
• Applies to services and plan years starting January 1, 2027.

• Medicaid Coverage (Title XIX of the Social Security Act):
• Redefines "medically accepted indication" for covered outpatient drugs to include uses for rare diseases or conditions that are supported by peer-reviewed literature, clinical guidelines, or experts from relevant medical societies, provided they are not contraindicated in compendia or FDA labeling.
• Makes conforming changes to reference "sources" instead of just compendia for drug evaluations.
• Applies to drugs furnished on or after January 1, 2027.

• Private Health Insurance Coverage (Title XXVII of the Public Health Service Act, ERISA, and Internal Revenue Code):
• Requires group health plans and health insurance issuers to provide an expedited appeal process (under existing rules for timely reviews) for denials of coverage for FDA-approved or licensed drugs/biological products used for rare diseases or conditions.
• Coverage must be supported by the drug's FDA-approved labeling or peer-reviewed literature/clinical guidelines, and not unfavorably reviewed in compendia or listed as a contraindication.
• Appeals can be initiated by patients, beneficiaries, enrollees, designees, or prescribing physicians.
• Applies to plan years beginning on or after January 1, 2027, with amendments to ERISA (for employer-sponsored plans) and the tax code (for compliance enforcement).

Significant Changes to Existing Law

• Broadened Coverage Criteria: Previously, coverage under Medicare and Medicaid was largely limited to FDA-approved uses or those listed in specific drug compendia. This bill introduces a new pathway for off-label uses in rare diseases, relying on peer-reviewed evidence and expert input rather than strict FDA indications.
• Expedited Appeals in Private Insurance: Adds a specific, faster review process for rare disease drug denials, building on existing general appeal rights but tailoring them to this context. No similar expedited mandate existed before for rare conditions.
• Consistency Across Programs: Aligns definitions and standards for "medically accepted indications" across public and private insurance, promoting uniformity where rare disease treatments were previously inconsistently covered.

Potential Impacts

• On Government Agencies: The Centers for Medicare & Medicaid Services (CMS) and Department of Health and Human Services (HHS) will need to update coverage guidelines, potentially increasing administrative workload and program costs due to more approved claims for rare disease drugs.
• On Citizens: Patients with rare diseases (about 30 million Americans) gain better access to potentially life-saving treatments, reducing financial barriers and out-of-pocket costs. However, it may not lower drug prices directly.
• On Health Insurers and Providers: Insurers face higher coverage obligations and faster appeal timelines, which could raise premiums or costs. Providers benefit from clearer guidelines for prescribing off-label drugs.
• On International Relations: Minimal direct impact, though it may indirectly encourage global pharmaceutical innovation in rare diseases by expanding U.S. market access.

Main Stakeholders Affected

• Patients and Families: Individuals with rare diseases, who often face limited treatment options and insurance denials.
• Pharmaceutical Manufacturers: Companies developing drugs for rare conditions, as expanded coverage could boost demand and revenue.
• Health Insurers and Plans: Private insurers, Medicare, and Medicaid administrators, who must adjust policies and processes.
• Healthcare Providers: Doctors and specialists, particularly those in rare disease fields, who can more confidently prescribe evidence-based off-label treatments.
• Medical Societies and Researchers: Organizations providing clinical guidelines and peer-reviewed literature, which gain influence in coverage decisions.

Notable Legal, Constitutional, or Political Implications

• Legal Implications: Strengthens patient protections by mandating evidence-based coverage for off-label uses, potentially reducing litigation over denials. It relies on existing FDA and compendia standards to avoid conflicts with drug approval laws, but could face challenges if insurers argue it increases regulatory burdens.
• Constitutional Implications: None significant; the bill operates within Congress's authority to regulate interstate commerce and health programs, without infringing on free speech, due process, or other rights.
• Political Implications: Bipartisan introduction (by Senators Tillis and Heinrich) highlights cross-party support for rare disease advocacy. It addresses equity in healthcare access, potentially influencing future drug pricing and orphan drug (rare disease) policies, but may spark debates on federal spending versus insurance costs.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Tillis, Thomas [R-NC]

Cosponsors (1)

Sen. Heinrich, Martin [D-NM]

Recent Actions

• 2025-12-17: Read twice and referred to the Committee on Finance.
• 2025-12-17: Introduced in Senate

Bill Versions

• Providing Realistic Opportunity To Equal and Comparable Treatment for Rare Act — issued 2025-12-17 — PDF (10 pages)